Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Melphalan for Retinoblastoma
NCT04342572Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melphalan in retinoblastoma (Rb), sponsored by Washington University School of Medicine. Primary endpoint: Feasibility of intra-arterial chemotherapy at 32 months. Started Aug 2020; status: completed.
02
Drugs
melphalan
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT04342572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342572.